The press release has successfully developed an aging cell clearance vaccine-the possibility of treatment in age-related diseases such as Alzheimer's disease-

In this study, we first comprehensively analyzed the genetic information of aging human vascular endothelial cells in order to determine the aging antigen specifically expressed in aging cells. Among the candidates, we have analyzed the GPNMB aging antigen, which shows that it is related to human aging. The results showed that GPNMB increased not only in human aging vascular endothelial cells, but also in vascular and visceral adipose tissues of atherosclerotic mice and aged mice. We also found that its expression was also increased in the blood vessels of elderly patients with arteriosclerosis.

Next, in order to verify the feasibility of anti-aging therapy for GPNMB, we prepared a genetically modified model mouse, which can selectively remove GPNMB positive aging cells by drugs. On the basis of feeding the mouse with obesity, the GPNMB positive senescent cells were selectively removed by medicine. it was found that the abnormal glucose metabolism and arteriosclerosis caused by obesity were improved.

Therefore, we are committed to developing an aging cell scavenging vaccine against GPNMB (figure 1). Among several designed vaccines, the vaccines that significantly increased the titer of GPNMB antibody were screened. When the vaccine was inoculated into mice on an obese diet, it was found that with the removal of aging cells accumulated in visceral fat, chronic inflammation in adipose tissue was improved, thereby improving abnormal glucose metabolism. In addition, in the atherosclerotic model mice, the accumulation of aging cells was found in the focus of arteriosclerosis, but it was found that the aging cell scavenging vaccine could remove the aging cells, and the focus of arteriosclerosis shrank with the improvement of chronic inflammation. In addition, the state of the flakes in the aged mice after vaccination was observed, and the progress of the slices was inhibited compared with the unvaccinated mice. The effect of prolonging life was confirmed by vaccination of presenile model mice (figure 2). Finally, in the comparative experiment with senescent cell scavengers, we also found that senescent cell scavenging vaccine had less side effects and longer effect.

According to the above results, the senescent cell removal vaccine targeting aging antigens such as GPNMB is expected to become a new treatment for age-related diseases.